Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

Philip D Harvey, R. S E Keefe

Research output: Contribution to journalArticle

539 Citations (Scopus)

Abstract

Objective: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. Method: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. Results: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. Conclusions: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.

Original languageEnglish
Pages (from-to)176-184
Number of pages9
JournalAmerican Journal of Psychiatry
Volume158
Issue number2
DOIs
StatePublished - Feb 14 2001
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Research Personnel
Clinical Trials
Aptitude
Cognition
Publications
Industry
Therapeutics
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. / Harvey, Philip D; Keefe, R. S E.

In: American Journal of Psychiatry, Vol. 158, No. 2, 14.02.2001, p. 176-184.

Research output: Contribution to journalArticle

@article{4739799b90484eea9986f418635fee00,
title = "Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment",
abstract = "Objective: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. Method: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. Results: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. Conclusions: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.",
author = "Harvey, {Philip D} and Keefe, {R. S E}",
year = "2001",
month = "2",
day = "14",
doi = "10.1176/appi.ajp.158.2.176",
language = "English",
volume = "158",
pages = "176--184",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

AU - Harvey, Philip D

AU - Keefe, R. S E

PY - 2001/2/14

Y1 - 2001/2/14

N2 - Objective: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. Method: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. Results: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. Conclusions: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.

AB - Objective: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. Method: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. Results: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. Conclusions: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.

UR - http://www.scopus.com/inward/record.url?scp=0035140610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035140610&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.158.2.176

DO - 10.1176/appi.ajp.158.2.176

M3 - Article

C2 - 11156796

AN - SCOPUS:0035140610

VL - 158

SP - 176

EP - 184

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -